Otsuka America Pharmaceutical - Publications - Faculty & Research - Harvard Business School

Filter Results: (339)

Filter Results: (339)

Show Results For

← Page 13 of 339 Results →

August 2022
Article

Availability of New Medicines in the U.S. and Germany From 2004 to 2018

By: Katharina Blankart, Huseyin Naci and Amitabh Chandra

Importance: Germany's unique approach to coverage determination and pricing has ensured that effective medicines remain on the market, often at prices reduced through negotiation. However, less is known about trade-offs of this approach with regard to initial... View Details

Keywords: Market Entry and Exit; Price; Market Timing; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; United States; Germany

Register to Read

September 1997 (Revised October 1997)
Case

Bayer AG (A)

By: John A. Quelch

Bayer's senior executives convene in Germany to consider submitting a $1 billion bid that would recover the Bayer brand name and trademark cross in North America, both of which were confiscated by the U.S. government after World War I. The group also sets out to assess... View Details

Keywords: Management Teams; Brands and Branding; War; Communication; Trademarks; Acquisition; Government and Politics; Pharmaceutical Industry; Pharmaceutical Industry; Germany; North America; United States

Find at Harvard

June 2012
Case

GlaxoSmithKline in Brazil: Public-Private Vaccine Partnerships

By: Arthur A. Daemmrich and Ian McKown Cornell

Three years into a major public-private partnership between GlaxoSmithKline and Fiocuz, Brazil's principal health institute, the company assesses technology transfer and joint research under the agreement. GSK was selling its Synflorix vaccine (against pediatric... View Details

Keywords: Public-Private Partnerships; Business and Government Relations; Foreign Direct Investment; Health Care and Treatment; Globalized Firms and Management; Pharmaceutical Industry; Pharmaceutical Industry; Brazil

November 2009 (Revised December 2009)
Case

GTC Biotherapeutics: Developing Medicines in the Milk of Goats

By: Ray A. Goldberg and Sarah Morton

GTC is the first company in the animal world to receive FDA approval of a transgenic pharmaceutical. What are the implications for other firms in plants and animals and their opportunities to produce new medicines in an economical and safe fashion? View Details

Keywords: Health Care and Treatment; Animal-Based Agribusiness; Plant-Based Agribusiness; Science-Based Business; Medical Specialties; Product; Technological Innovation; Pharmaceutical Industry; Pharmaceutical Industry; United States

26 Jul 2016
Working Paper Summaries

The Impact of the Entry of Biosimilars: Evidence from Europe

Keywords: by Fiona Scott Morton, Ariel Dora Stern, and Scott Stern; Pharmaceutical; Pharmaceutical; Pharmaceutical

May 2015
Case

Transforming Alkermes into a Global Biopharmaceutical Company

By: C. Fritz Foley and Nicholas Haas

In the summer of 2011, Jim Frates, CFO of Alkermes faced choices about how to finance the acquisition of Dublin, Ireland-based Elan Drug Technologies (EDT)—a deal that was expected to close in the fall. The case describes the history of Alkermes, provides information... View Details

Keywords: Financing; Debt; Merger; CFO; Financial Management; Pharmaceutical Industry; Pharmaceutical Industry; United States; Europe

February 1997 (Revised June 1999)
Teaching Note

Massachusetts General Hospital: CABG Surgery (A) TN

By: Steven C. Wheelwright

Teaching Note for (9-696-015). View Details

Keywords: Pharmaceutical Industry; Pharmaceutical Industry; Massachusetts

November 1995 (Revised March 2004)
Case

Massachusetts General Hospital: CABG Surgery (A)

By: Steven C. Wheelwright and James Weber

A cross-functional team at Massachusetts General Hospital tries to reengineer the service delivery process (the "care path") for heart bypass surgery (CABG) in order to shorten hospital stays (and lower costs) while maintaining/enhancing the quality of care provided. View Details

Keywords: Health Care and Treatment; Medical Specialties; Business Processes; Mission and Purpose; Product Positioning; Product Marketing; Management Practices and Processes; Customer Satisfaction; Service Delivery; Service Operations; Fair Value Accounting; Ethics; Pharmaceutical Industry; Pharmaceutical Industry; Massachusetts

January 2014
Supplement

Amgen Inc.: Pursuing Innovation and Imitation? (B)

By: Ian Mackenzie

The (B) case reveals that Sharer decided that Amgen should enter the emerging biosimilars business. However, he took the better part of a year to syndicate the decision across the senior team while in parallel investing in some time-critical process development. The... View Details

Keywords: Corporate Strategy; Pharmaceutical Industry; Pharmaceutical Industry; United States

May 2012 (Revised August 2014)
Case

McKesson

By: Regina E. Herzlinger and Natalie Kindred

McKesson, a large, diversified drug distribution and health care IT company, is considering development of new business offerings to help private practice physicians remain independent. The company, with $122 billion in 2010 revenues, just made its first foray into... View Details

Keywords: Health Care Industry; Health Care Policy; Organizational Transformations; Health Services; Health Care and Treatment; Business Model; Service Operations; Change Management; Corporate Strategy; Information Technology; Policy; Pharmaceutical Industry; Pharmaceutical Industry; United States

December 2005 (Revised October 2006)
Case

Pharmacy Service Improvement at CVS (A)

CVS's retail pharmacy operations are functioning poorly and dissatisfying customers. Many customers are defecting as a result. A pharmacy service improvement team has documented the current prescription fulfillment process, its exception rates, and the problems... View Details

Keywords: Information Technology; Performance Improvement; Business Processes; Pharmaceutical Industry; Pharmaceutical Industry; United States

April 1993 (Revised May 1994)
Case

Genzyme Corporation: Strategic Challenges with Ceredase

Genzyme Corp., one of the largest biotechnology companies, has succeeded in developing, manufacturing, and commercializing its first therapeutic, a treatment for a rare genetic disease. Analysis of the case requires students to identify and understand how Genzyme has... View Details

Keywords: Risk Management; Risk and Uncertainty; Corporate Strategy; Technology; Health; Product Development; Pharmaceutical Industry; Pharmaceutical Industry; United States

05 Jan 2011
Op-Ed

Funding Unpredictability Around Stem-Cell Research Inflicts Heavy Cost on Scientific Progress

In light of the latest developments of the on-again, off-again, on-again government funding of human embryonic stem-cell research, it is time to consider the devastating implications of this chaotic funding environment. And to do that, one needs to understand how a... View Details

Keywords: by William Sahlman; Pharmaceutical; Pharmaceutical; Pharmaceutical

01 Dec 2003
News

The Next Big Thing

life-sciences center of the world, by virtue of its unsurpassed “cluster” of world-renowned universities and teaching hospitals; medical-device, biotech, and pharmaceutical companies; financial firms; and skilled workers. “The leadership... View Details

Keywords: life sciences; Scientific Research and Development Services

May 1992
Teaching Note

RU 486 (A) and (B), Teaching Note

By: Joseph L. Badaracco Jr.

Teaching Note for (9-391-050) and (9-391-051). View Details

Keywords: Pharmaceutical Industry; Pharmaceutical Industry; France; Germany; United States

October 1990 (Revised April 1991)
Case

RU 486 (A)

By: Joseph L. Badaracco Jr.

Describes the factors faced by Roussel UCLAF, a French drug company, in deciding whether and how to market a controversial new drug, RU 486, which is often called "the French abortion pill." Roussel's decision involved its relations with the French government, its... View Details

Keywords: Judgments; Ethics; Product Launch; Negotiation; Outcome or Result; Performance; Business and Government Relations; Pharmaceutical Industry; Pharmaceutical Industry; France; Germany; United States

July 2014
Teaching Note

Vaxess Technologies, Inc.

By: John A. Quelch

Keywords: Marketing Innovations; Entrepreneurship; Innovation and Management; Business Startups; Marketing Strategy; Pharmaceutical Industry; Pharmaceutical Industry; North and Central America

01 Mar 2003
News

Inside the Revolution

care and life sciences issues, with the lion’s share focusing on the biotech and pharmaceutical industries. More than twenty HBS professors from different disciplines have contributed to this effort, which Pisano says is analogous to the... View Details

Keywords: Garry Emmons; Eileen McCluskey; Jonathan West; Life Sciences Project; LSP; Colleges, Universities, and Professional Schools; Educational Services

February 2006 (Revised February 2009)
Case

AIDS in Brazil

By: Rohit Deshpande and Ricardo Reisen de Pinho

Abbott Labs has reached an impasse with the Brazilian government in negotiations over the pricing of a new anti-AIDS drug, Kaletra. The Brazilian government threatens compulsory licensing unless Abbott drastically reduces the price of Kaletra. View Details

Keywords: Price; Government and Politics; Health Care and Treatment; Health Disorders; Rights; Negotiation; Business and Government Relations; Pharmaceutical Industry; Brazil

03 Jan 2007
First Look

First Look: January 3, 2007

analysts from Gradient Analytics and Banc of America face charges of stock price manipulation from Biovail, a Canadian pharmaceutical company. Gradient and BofA produced negative reports on Biovail's... View Details

Keywords: Sean Silverthorne

←
13
14
15
16
17
→